MedTrace Logo

Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A

NCT00803816 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-05-27

No results posted yet for this study

Summary

Study efficacy of everolimus on course of uveitis:

* obtain quiescence of inflammation after start of treatment
* duration to obtain quiescence of inflammation
* number of patients with quiescence of inflammation

Conditions

  • Uveitis

Interventions

DRUG

everolimus

everolimus 1.0 - 2.5mg oral daily dosage

Sponsors & Collaborators

  • Carsten Heinz

    lead OTHER

Principal Investigators

  • Arnd Heiligenhaus, MD · Department of Ophthalmology at St. Franziskus Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2010-09-30
Completion
2010-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00803816 on ClinicalTrials.gov